Oculis Holding AG (NASDAQ:OCSAW – Get Free Report) shares traded up 2.9% during mid-day trading on Wednesday. The stock traded as high as $2.45 and last traded at $2.45. 3,800 shares were traded during mid-day trading, a decline of 33% from the average daily volume of 5,668 shares. The stock had previously closed at $2.38.
Oculis Stock Performance
The business’s fifty day moving average is $3.30 and its 200 day moving average is $9.75.
About Oculis
Oculis is a clinical-stage biopharmaceutical company focused on developing innovative ophthalmic treatments. The company uses its proprietary OPTIREACH technology platform to develop eye-drop formulations designed to deliver medicines to tissues at the back of the eye, potentially addressing conditions that traditionally require injections or other invasive procedures.
Oculis’ development portfolio has included treatments for retinal diseases, glaucoma and ocular surface disorders. Its investigational products have targeted conditions such as diabetic macular edema, dry eye disease and neurodegenerative eye diseases.
Featured Stories
- Five stocks we like better than Oculis
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
